A chromatographic purification process for bispecific antibodies
By using elution buffer containing additives and linear pH gradient in bispecific antibodies in the chromatographic purification process of bispecific antibodies, the problem of homodimer removal in bispecific antibodies is solved, and efficient purification effect is achieved and the drug is improved Reliability of preparation.
Patent Information
- Application Number
- CN202011342663.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-11-26
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-11-26
AI Technical Summary
There is a lack of effective purification methods in the prior art to remove homodimers in bispecific antibodies, resulting in low purification efficiency during the preparation of bispecific antibody drugs and a lack of reliable choices.
A chromatographic purification process that involves processing chromatographic fillers, rinsing with equilibrium buffer and elution buffer containing additives to enhance bispecificity by generating linear pH gradients and additives such as arginine, glycine, etc. Purification efficiency of sex antibodies.
It realizes efficient removal of homodimers in bispecific antibodies, improves the purification efficiency during drug preparation, and provides more reliable purification options for bispecific antibody drugs, achieving 98% purity and higher recovery. Rate.
Smart Images

Figure BDA0002798974090000061 
Figure BDA0002798974090000071 
Figure BDA0002798974090000081
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a chromatography purification process for a bispecific antibody. Background Art
[0002] With the continuous development of biological drugs, therapeutic antibodies, especially bispecific antibodies, have become the main choice of drugs for patients with cancer, autoimmunity, inflammation and various other diseases. Bispecific antibodies (BiAb) are artificial antibodies containing two specific antigen binding sites, which can specifically recognize and bind to two different antigens or antigenic epitopes. They can build a bridge between target cells and functional molecules (cells), produce directional effector functions, redirect specific immune cells to tumor cells to enhance tumor killing, or simultaneously block two different mediators / pathways to play unique or overlapping functions.
[0003] The anti-GPC3 and anti-CD3 bispecific antibodies currently under development have two different variable regions, one of which recognizes and binds to the tumor antigen GPC3, and the other is used to bind to T cells. The bispecific antibody acts as a "connector arm" to summon T cells to the tumor site. At the same time, the antibody adopts a common light chain structure design. The heavy chains of the antibodies targeting the two targets have the same light chain, which will not cause light and heavy chain mismatches in antibody expression pairing.
[0004] Although common light chain bispecific antibodies have great advantages in drugability and production process control, their structure is more complex than monoclonal antibodies due to the use of two different heavy chains. In the process of preparing bispecific antibodies, it is also easier to produce various homodimers. Therefore, separation and purification of the target antibody culture is an essential step in its production process. However, in the prior art, there are few reports on purification methods of common light chain bispecific antibodies.
[0005] Patent CN101180317B discloses a method for purifying immunoglobulins by ion exchange chromatography. The chromatography method uses a weak ion exchange resin and a single-step elution method to purify immunoglobulins, and determines the salt concentration of immunoglobulins in a single-step elution from the ion exchange resin.
[0006] Patent CN107922476A discloses a method for purifying bispecific antibodies from a mixture of monospecific antibodies, that is, by a multi-mixed chromatography purification method, a bispecific antibody (consisting of a single heavy chain and two different light chains) is separated from a mixture containing a monospecific antibody having two κ light chains or parts thereof and a monospecific antibody having two λ light chains or parts thereof.
[0007] Therefore, it is necessary to provide a simple and effective chromatography purification process for purifying bispecific antibody homodimers, which can improve the efficiency of removing homodimers during the preparation of bispecific antibody drugs and provide a more reliable option for the purification process of bispecific antibody drugs. Summary of the invention
[0008] In order to solve the above problems existing in the prior art, the present invention discloses a chromatography purification process for a bispecific antibody.
[0009] The chromatographic purification process of a bispecific antibody according to the present invention comprises the following steps:
[0010] Step 1, treating the chromatography filler and loading the sample;
[0011] Step 2, eluting with equilibration buffer;
[0012] In step 3, the product is eluted using an elution buffer containing additives and collected.
[0013] Furthermore, the bispecific antibody is a bispecific antibody of anti-GPC3 and anti-CD3.
[0014] Furthermore, the specific operation method of step 1 is:
[0015] 1a, packing the chromatography filler into the column, and washing the column with 3-50 column volumes of equilibration buffer;
[0016] 1b, disinfect the chromatography column with 2-4 column volumes of 1M NaOH solution;
[0017] 1c, wash the column with 3-6 column volumes of equilibration buffer;
[0018] 1d, sample loading, retention time 5±1min.
[0019] Furthermore, the chromatography filler is selected from Capto MMC, Diamond SP Mustang or Capto SImpAct.
[0020] Furthermore, the elution buffer comprises elution buffer A and elution buffer B; the elution buffer A is composed of sodium citrate, sodium dihydrogen phosphate and tris (hydroxymethylaminomethane); the elution buffer B is composed of sodium citrate, sodium dihydrogen phosphate and tris (hydroxymethylaminomethane).
[0021] Furthermore, the elution buffer generates a linear pH gradient when passing through the elution product.
[0022] Furthermore, the pH range of the elution buffer A is 4.0-6.0, and the pH range of the elution buffer B is 9.0-11.0.
[0023] Furthermore, the pH range of the elution buffer A is 4.5-5.5, and the pH range of the elution buffer B is 9.5-10.5.
[0024] Furthermore, the elution buffer further contains additives.
[0025] Furthermore, the additive is alcohol, sugar or amino acid.
[0026] Furthermore, the amino acid is arginine, glycine, histidine, proline, phenylalanine or tyrosine.
[0027] Further, the molar concentration of the additive is 1-100 mM; preferably, the molar concentration of the additive is 2-50 mM; more preferably, the molar concentration of the additive is 5-40 mM; further preferably, the molar concentration of the additive is 10-30 mM.
[0028] Furthermore, the equilibration buffer in step 2 is 3-6 times the column volume.
[0029] Furthermore, the balancing buffer is sodium citrate, sodium dihydrogen phosphate and tris(hydroxymethyl)aminomethane, pH 5.0.
[0030] Furthermore, the elution buffer in step 3 is 10-100 times the column volume.
[0031] Therefore, the present invention relates to the following embodiments:
[0032] 1. A chromatography purification process for a bispecific antibody, characterized in that it comprises the following steps:
[0033] Step 1, treating the chromatography filler and loading the sample;
[0034] Step 2, eluting with equilibration buffer;
[0035] In step 3, the product is eluted using an elution buffer containing additives and collected.
[0036] 2. The chromatography purification process according to claim 1, characterized in that the bispecific antibody is a bispecific antibody of anti-GPC3 and anti-CD3.
[0037] 3. The chromatography purification process according to claim 1 or 2, characterized in that the specific operation method of step 1 is:
[0038] 1a, packing the chromatography filler into the column, and washing the column with 3-50 column volumes of equilibration buffer;
[0039] 1b, disinfect the chromatography column with 2-4 column volumes of 1M NaOH solution;
[0040] 1c, wash the column with 3-6 column volumes of equilibration buffer;
[0041] 1d, sample loading, retention time 5±1min.
[0042] 4. The chromatography purification process according to claims 1-3, characterized in that the chromatography filler is selected from CaptoMMC, Diamond SP Mustang or Capto S ImpAct.
[0043] 5. The chromatography purification process according to claims 1-4, characterized in that the elution buffer comprises elution buffer A and elution buffer B; the elution buffer A is composed of sodium citrate, sodium dihydrogen phosphate and tris(hydroxymethyl)aminomethane; the elution buffer B is composed of sodium citrate, sodium dihydrogen phosphate and tris(hydroxymethyl)aminomethane.
[0044] 6. The chromatography purification process according to claim 5, characterized in that the elution buffer generates a linear pH gradient when passing through the elution product.
[0045] 7. The chromatography purification process according to claim 5 or 6, characterized in that the pH range of the elution buffer A is 4.0-6.0, and the pH range of the elution buffer B is 9.0-11.0.
[0046] 8. The chromatography purification process according to claim 5 or 6, characterized in that the pH range of the elution buffer A is 4.5-5.5, and the pH range of the elution buffer B is 9.5-10.5.
[0047] 9. The chromatography purification process according to claims 1-8, characterized in that the elution buffer further contains an additive.
[0048] 10. The chromatography purification process according to claim 9, characterized in that the additive is alcohol, sugar or amino acid.
[0049] 11. The chromatography purification process according to claim 10, characterized in that the amino acid is arginine, glycine, histidine, proline, phenylalanine or tyrosine.
[0050] 12. The chromatography purification process according to claim 10, characterized in that the molar concentration of the additive is 1-100 mM; preferably, the molar concentration of the additive is 2-50 mM; more preferably, the molar concentration of the additive is 5-40 mM; further preferably, the molar concentration of the additive is 10-30 mM.
[0051] 13. The chromatography purification process according to claim 1 or 2, characterized in that the equilibration buffer in step 2 is 3-6 times the column volume.
[0052] 14. The chromatography purification process according to claim 1 or 2, characterized in that the equilibrium buffer is sodium citrate, sodium dihydrogen phosphate and tris(hydroxymethyl)aminomethane, pH 5.0.
[0053] 15. The chromatography purification process according to claim 1, characterized in that the elution buffer in step 3 is 10-100 times the column volume.
[0054] the term
[0055] A "common light chain" or "common light chain" refers to a polypeptide containing a light chain variable region that is capable of stably and independently pairing with at least two different heavy chain polypeptides and thereby generating, in each independent case, an antigen binding domain comprising a heavy chain variable region and a light chain variable region of each heavy chain polypeptide. Thus, the two copies of the common light chain are each capable of stably pairing with a first heavy chain polypeptide and a second heavy chain polypeptide, so that the bispecific antibody is in a natural form, such as an IgG isotype form, such as an IgG1 form, an IgG2 form, an IgG3 form, and / or an IgG4 form, wherein the bispecific antibody is specific for two different antigens.
[0056] "Homodimer" refers to an antibody comprising two identical heavy chains having one of two antigenic specificities, and in certain embodiments, refers to an antibody specific for GPC3, or refers to an antibody specific for CD3.
[0057] “Amino acids” are named by three-letter or one-letter codes as follows: alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine (Cys, C), glutamine (Gln, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine (His, H), isoleucine (Ile, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y) and valine (Val, V).
[0058] A "buffer" is a buffered solution that resists changes in pH through the action of its acid-base conjugate components.
[0059] An "equilibration buffer" herein is a buffer used to prepare the chromatography solid phase.
[0060] The "elution buffer" is used to elute the protein from the chromatography matrix, that is, to elute the target protein from the solid phase. The conductivity and / or pH of the elution buffer can elute the target protein from the ion exchange resin.
[0061] "Linear elution" refers to a method in which, for example, in certain embodiments, the total volume of elution buffer A and elution buffer B remains unchanged throughout the elution process, and the volume fraction of elution buffer B is linearly related to time, that is, the volume of elution buffer B increases linearly with time.
[0062] A "salt" is a compound formed by the interaction of an acid and a base.
[0063] Beneficial effects of the present invention
[0064] The present invention provides a new and simple and effective chromatography purification process for removing bispecific antibody homodimers, which can improve the efficiency of removing homodimers in the preparation process of bispecific antibody drugs and provide a more reliable option for the purification process of bispecific antibody drugs. DETAILED DESCRIPTION
[0065] The present invention is described in detail below in conjunction with specific examples, but these examples are not intended to limit the scope of the present invention. The experimental methods of the present invention that do not specify specific conditions are usually carried out under conventional conditions, and the test materials used in the following examples, unless otherwise specified, are purchased from conventional biochemical reagent stores.
[0066] Example 1 Preparation of Antibodies
[0067] Take out the cell line 105-102-7 from liquid nitrogen, thaw quickly in a 37°C water bath, transfer the cells to a shake flask for culture, and the cell inoculation density is 0.4-1.2×10 6 cells / ml.
[0068] The cells were cultured in a shake flask and subcultured every 2 days. Shake flasks of different specifications were replaced according to the culture volume. The shaker parameters were 37°C, 5% CO2, and 115 rpm. When the final cell density reached 3-6×10 6 cells / ml, cell viability greater than 90%, and transferred to a fermenter for culture.
[0069] The inoculation density of the fermentation tank is 0.8~1.2×10 6 cells / ml, temperature 37°C, rotation speed 180-250rpm, pH 6.8-7.2, dissolved oxygen (pO2) 50%. When the cell density is ≥10×10 6When the cell viability is 100 cells / ml, the culture temperature is lowered to 32°C. In order to ensure that the cells have sufficient nutrition to maintain their high viability and produce the target protein, 3% of the initial culture volume of feed medium is added on the 4th, 6th, 8th and 10th days of culture. In order to avoid the obvious effect of low glucose content on cell viability, 30% (m / v) glucose solution is added to the reactor to maintain the glucose content in the culture medium at 4g / L. When the cell viability drops to about 80%, the cell fermentation liquid is harvested.
[0070] The harvested fermentation broth was centrifuged at 8000-12000 rpm for 30 minutes, filtered through a 0.45 um filter membrane, and then subjected to protein A affinity chromatography (Borgron AT Protein A) to obtain anti-GPC3 and anti-CD3 bispecific antibodies (homodimer impurities were about 15%).
[0071] Example 2 Addition of salt and different additives to the elution buffer
[0072] The purification effects of salt and additives on homodimers of anti-GPC3 and anti-CD3 bispecific antibodies were investigated by adding different salt additives to the elution buffer solution.
[0073] Chromatography conditions:
[0074] Filling: Diamond SP Mustang
[0075] Column volume: 6.18ml
[0076] Flow rate: 1.2ml / min
[0077] Sample: Bispecific antibody against GPC3 and CD3, homodimer impurity about 15%
[0078] Equilibration buffer: 50 mM NaAc-HAc, pH 5.0
[0079] Elution buffer A: 50 mM NaAc-HAc, pH 5.0
[0080] Elution buffer B: 50 mM NaAc-HAc, 1 M NaCl, pH 5.0
[0081] The bispecific antibody of anti-GPC3 and anti-CD3 (homodimer impurity of about 15%) was loaded, and after the loading step, the column was washed with 3 column volumes of equilibration buffer at a flow rate of 1.2 ml / min. The homodimer in the bispecific antibody of anti-GPC3 and anti-CD3 was eluted by linear elution, wherein the pH value in the mobile phase was kept constant. In schemes 1 and 3, the volume fraction of elution buffer B was linearly increased from 5% to 50%, and in scheme 2, the volume fraction of elution buffer B was linearly increased from 0% to 50%.
[0082] The eluted samples were collected by the responsible person to determine the purity. Products with purity ≥98% were qualified samples. The recovery rate of qualified samples was calculated. The results are shown in Table 1.
[0083] Table 1 Purification results using different additives
[0084]
[0085] The results show that when only NaCl is added to the elution buffer without using additives, there is no separation effect for the purification of the target product and homodimer; when ethanol and sucrose are used as additives, there is a separation effect, but the recovery rate is relatively low; when L-Arg is used as an additive, not only is the separation effect better, the purity of the target product is high, but the recovery rate is also higher than when no additives are used.
[0086] Example 3 pH linear elution
[0087] By adding different additives to the elution buffer solution supplemented with NaCl, the effect of the additives on the purification of homodimers in the anti-GPC3 and anti-CD3 bispecific antibodies was examined.
[0088] Chromatography conditions:
[0089] Column volume: 6.18ml
[0090] Flow rate: 1.2ml / min
[0091] Sample: Bispecific antibody against GPC3 and CD3, homodimer impurity about 15%
[0092] Equilibration buffer: 20 mM sodium citrate, 20 mM NaH2PO4, 20 mM Tris
[0093] Elution buffer A: 20 mM sodium citrate, 20 mM NaH2PO4, 20 mM Tris
[0094] Elution buffer B: 20 mM sodium citrate, 20 mM NaH2PO4, 20 mM Tris
[0095] The bispecific antibody of anti-GPC3 and anti-CD3 (homodimer impurity of about 15%) was loaded, and after the loading step, the column was washed with 3 column volumes of equilibration buffer at a flow rate of 1.2 ml / min. The homodimer in the bispecific antibody of anti-GPC3 and anti-CD3 was eluted by linear pH elution, and the volume fraction of elution buffer B was linearly increased from 0% to 100%. No additive was added in Scheme 5, and the additive used in Schemes 6, 7, 8 and 9 was 20 mM glycine.
[0096] The eluted samples were collected by the responsible person to determine the purity. Products with a purity of ≥98% were qualified samples. The recovery rate of qualified samples was calculated. The results are shown in Table 2.
[0097] Table 2 Purification results using linear gradient method with additives
[0098]
[0099]
[0100] The results show that when the homodimers in the anti-GPC3 and anti-CD3 bispecific antibodies were eluted by the linear pH elution method, when no additives were used, the target product and the homodimer were purified, and the separation effect was relatively good, but the recovery rate was relatively low; when 20mM glycine was used, not only the separation effect was good, but also the recovery rate of qualified products was greatly improved. Compared with the solution in Example 1 without adjusting the pH value, the solution in Example 2 has better separation effect and higher recovery rate through the linear pH gradient change.
[0101] It should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the scope of the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A chromatography purification process for a bispecific antibody, characterized in that: The following steps are involved: Step 1, treating the chromatography filler and loading the sample; Step 2, washing with an equilibrium buffer; the equilibrium buffer is: 20 mM sodium citrate, 20 mM NaH2PO4, 20 mM Tris; Step 3, eluting the product using an elution buffer containing an additive, and collecting the product; The bispecific antibody is a bispecific antibody of anti-GPC3 and anti-CD3; the elution buffer comprises an elution buffer A and an elution buffer B; the elution buffer A is composed of 20 mM sodium citrate, 20 mM sodium dihydrogen phosphate and 20 mM tris(hydroxymethyl)aminomethane, with a pH of 5.0; the elution buffer B is composed of 20 mM sodium citrate, 20 mM sodium dihydrogen phosphate and 20 mM tris(hydroxymethyl)aminomethane, with a pH of 10.0; the additive is 20 mM glycine; the chromatography conditions are: column volume: 6.18 mL; flow rate: 1.2 mL / min; The elution buffer produces a linear pH gradient as it passes through the elution product.
2. The chromatography purification process according to claim 1, characterized in that: The specific operation method of step 1 is: 1a, packing the chromatography filler into the column, and washing the column with 3-50 column volumes of equilibration buffer; 1b, disinfect the chromatography column with 2-4 column volumes of 1M NaOH solution; 1c, wash the column with 3-6 column volumes of equilibration buffer; 1d, sample loading, retention time 5±1min.
3. The chromatography purification process according to claim 1, characterized in that: The chromatography filler is selected from Capto MMC, Diamond SP Mustang or Capto S ImpAct.
